BPC-157 and "research peptides": the evidence and the law

BPC-157 is a chain of 15 amino acids. Its full sequence is published in a US government policy document: glycine, glutamic acid, three prolines, glycine, lysine, proline, alanine, two aspartic acids, alanine, glycine, leucine and valine. It is usually described as a fragment of a protein found in human gastric juice, and it is made synthetically for sale. TB-500 is a much shorter seven-amino-acid fragment related to thymosin beta-4, a naturally occurring protein.

Both are sold online, in gyms and through clinics, mostly as powders in vials to be mixed with water and injected, and often labelled "for research use only". They are promoted for injury recovery, gut problems and "healing". Neither is an approved medicine in the US, the UK, the UAE or South Africa, and neither is a food supplement.

The short answer: the case for BPC-157 rests almost entirely on rat studies. Across every published human report, about 30 people have received it, none of them in a randomised, placebo-controlled trial. TB-500 has even less. A late-October 2026 US policy change lets some American pharmacies compound six of these peptides under conditions. That is a decision not to prosecute while rules are written. It is not evidence that they work, and it does not change their status anywhere else.

What the evidence says

Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies), Insufficient (too little human research to judge) and Evidence of harm. Animal and cell studies do not count towards a grade.

Muscle, tendon and ligament recovery: Insufficient

A 2025 systematic review in HSS Journal screened 544 articles on BPC-157 and included 36 studies. Thirty-five were animal or laboratory studies. In those models, BPC-157 improved healing measures in muscle, tendon, ligament and bone injuries. Only one study involved people, and the review found no clinical safety data at all.

That single human study was a retrospective chart review from one clinic in Orlando, Florida. Sixteen patients with knee pain of mixed causes, who had BPC-157 injected into the knee alone or with thymosin beta-4, were later asked by phone to rate their pain. Of the 12 given BPC-157 alone, 11 reported significant improvement, and the HSS review counted 7 of 12 with relief lasting more than six months. There was no control group, no blinding and no standard measure of function, so it cannot separate the injection from time, placebo or other treatment.

A 2026 systematic review in Acta Orthopaedica Belgica searched four databases up to 1 June 2026 for any human study of BPC-157. It found three, with 30 participants in total: the knee chart review (16 people), a retrospective pilot of BPC-157 instilled into the bladder in people with interstitial cystitis (12 people) and an intravenous safety pilot (2 people). All three reported improvement in most participants and no treatment-related adverse events, but all were judged poor quality. The reviewers rated the overall certainty of evidence as very low and concluded that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials.

Safety in people: Insufficient

The only prospective safety study gave two adults, aged 58 and 68, an intravenous infusion of 10 mg of BPC-157 on one day and 20 mg the next. Both had used intravenous BPC-157 before. Neither reported side effects, and blood markers of heart, liver, kidney and thyroid function and blood glucose did not change over three days. Two people over three days cannot show that a substance is safe for repeated use over weeks or months, which is how it is usually sold.

According to the HSS review, BPC-157 has a half-life of less than 30 minutes, is broken down in the liver and is cleared by the kidneys. The HSS review notes that harm is still possible from unregulated manufacturing, contamination and the absence of clinical safety data.

TB-500: Insufficient

A 2026 review for orthopaedic and sports medicine doctors in the American Journal of Sports Medicine found that thymosin beta-4 and TB-500 promoted blood-vessel growth and tissue repair in animal models, but that human orthopaedic data were lacking. The authors concluded that indications, dosing, frequency and duration for these peptides remain unknown.

Epitalon, KPV, MOTS-c and Semax: Insufficient

These are the other four peptides in the US policy. HHS's own justification document describes their human records in limited terms: "limited controlled human exposure" for epitalon, a randomised placebo-controlled trial of an analogue of MOTS-c rather than MOTS-c itself, and, for Semax, an intranasal human record of several hundred people compiled by the FDA's own drug centre. HHS calls the FDA's safety concerns about several of them "mechanistic" or "inferential rather than observed", which also means the safety record is thin rather than reassuring. For each of the six, the FDA's Center for Drug Evaluation and Research (CDER) had recommended against adding it to the list of substances pharmacies may compound. The Pharmacy Compounding Advisory Committee voted in favour.

Why the product matters as much as the molecule

Grey-market vials are made outside medicines manufacturing rules, so the contents, strength and sterility of a given vial are unknown. The US policy says so directly: it describes "research-use-only peptides supplied by foreign manufacturers" as posing a safety risk to US patients, and it requires any compounded version to come from an FDA-registered manufacturer with a batch certificate covering identity, purity, potency, endotoxins, heavy metals and microbial contamination. Those are the checks a vial bought online usually lacks.

Side effects and safety

No human study of BPC-157 has been large enough or long enough to describe its side effects. The risks that can be named are those of injecting an unlicensed product of unknown quality: infection, contamination and the chance that the vial contains something other than what the label says. Report any suspected reaction to the MHRA Yellow Card scheme. If you have chest pain, difficulty breathing, a spreading red and hot area around an injection site with fever, or feel faint, call 999. For urgent advice that is not an emergency, call NHS 111.

Sport. BPC-157 is named on the World Anti-Doping Agency's 2026 Prohibited List under S0, non-approved substances, which covers any pharmacological substance with no current approval by any government health authority for human therapeutic use. Thymosin beta-4 and its derivatives, including TB-500, are listed under S2.3, growth factors. Both are prohibited at all times, in and out of competition. An athlete subject to anti-doping rules risks a ban from either.

UK regulatory status

In the UK the deciding law is the Human Medicines Regulations 2012. A product is a medicinal product if it is presented as treating or preventing disease, or if it is used with a view to restoring, correcting or modifying a physiological function through a pharmacological, immunological or metabolic action. A peptide injected for injury recovery fits that definition whatever the label says, and BPC-157 has no current approval for human therapeutic use from any government health authority, which is why WADA names it as a non-approved substance.

An unlicensed medicine can only be supplied in narrow circumstances, as a "special" ordered by a doctor, dentist or other appropriately qualified prescriber to meet the special needs of an individual patient under their care. One of the legal conditions for that exemption is that no advertisement relating to the product is published by anyone. Clinic web pages promoting peptide injections to the public sit outside that route, and the MHRA publishes the names of providers that have changed their advertising after MHRA action on unlicensed or prescription-only medicines.

Nothing like the US policy exists in the UK. BPC-157, TB-500 and the other four peptides are not authorised food supplements or novel foods, and the US decision does not change their UK status.

If a clinic offers you peptides

• Is this a licensed medicine for my condition, and if not, what is its legal status here?
• What human trials support it for the result being promised, and were they randomised and placebo-controlled?
• Who made the product, and can I see the batch certificate of analysis?
• Who is prescribing it, and have they reviewed my other medicines and health conditions?
• Am I subject to anti-doping rules through my sport or job?

You can find practitioners in our professionals directory, and check a doctor on the GMC register, a nurse on the NMC register or a pharmacist on the GPhC register before booking.

FAQ

Is BPC-157 legal in the UK?

It is not a licensed medicine. A product used to change how the body works is a medicine under UK law, and unlicensed medicines can only be supplied in narrow circumstances by a prescriber for an individual patient, without public advertising. A "research use only" label does not make human use lawful or safe.

Does BPC-157 work for tendon or muscle injuries?

In rats, often. In people, nobody knows yet. Three small studies with 30 people in total, none of them controlled, are the whole human record.

What did the US actually change?

In October 2026 HHS said it would not take enforcement action against US state-licensed pharmacies and doctors who compound six peptides, including BPC-157 and TB-500, if ten conditions are met. It is not an approval and applies only in the US.

Is oral BPC-157 safer than injecting it?

There are no human trials of oral BPC-157. The US policy itself notes that achieving adequate oral absorption of peptides is inherently difficult.

Can athletes use BPC-157 or TB-500?

No. Both are prohibited at all times on the 2026 WADA Prohibited List.